Press coverage about Mast Therapeutics (NYSE:MSTX) has trended somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Mast Therapeutics earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.3912281178556 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Shares of Mast Therapeutics (NYSE MSTX) traded down 5.28% during midday trading on Friday, hitting $0.13. 15,259,475 shares of the company were exchanged. The company’s 50 day moving average price is $0.12 and its 200 day moving average price is $0.11. Mast Therapeutics has a one year low of $0.07 and a one year high of $0.71.

ILLEGAL ACTIVITY NOTICE: “Mast Therapeutics (MSTX) Getting Somewhat Favorable Media Coverage, Report Finds” was reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at

About Mast Therapeutics

Mast Therapeutics, Inc is a biopharmaceutical company. The Company develops clinical-stage therapies for serious or life-threatening diseases with unmet needs. The Company focuses on developing new therapies for sickle cell disease, a chronic and genetic disorder classified as a rare, or orphan, disease in the United States of America and European Union, and for heart failure, a condition with an unmet need for treatment options.

Insider Buying and Selling by Quarter for Mast Therapeutics (NYSE:MSTX)

Receive News & Ratings for Mast Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.